Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label study of nipocalimab in children with generalized myasthenia gravis
jRCT2031220102Recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Aug 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
01
Overview
Open-label, single-arm trial of nipocalimab in myasthenia gravis (MG), sponsored by Janssen Pharmaceutical. Primary endpoints: Change from baseline in total serum IgG levels, Number of participants with infectious adverse events and 12 more. Started Aug 2022; status: recruiting.
02
Drugs
nipocalimab
03
Conditions
myasthenia gravis (MG)
Beyond the preview
Go deeper on jRCT2031220102.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031220102.